CA3011014A1 - Compositions and methods for generating an immune response to a tumor associated antigen - Google Patents

Compositions and methods for generating an immune response to a tumor associated antigen Download PDF

Info

Publication number
CA3011014A1
CA3011014A1 CA3011014A CA3011014A CA3011014A1 CA 3011014 A1 CA3011014 A1 CA 3011014A1 CA 3011014 A CA3011014 A CA 3011014A CA 3011014 A CA3011014 A CA 3011014A CA 3011014 A1 CA3011014 A1 CA 3011014A1
Authority
CA
Canada
Prior art keywords
sequence
taa
mva
vector
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3011014A
Other languages
English (en)
French (fr)
Inventor
Harriet Robinson
Arban Domi
Michael Hellerstein
Farshad Guirakhoo
Nathanael Paul McCurley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geovax Inc
Original Assignee
Geovax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geovax Inc filed Critical Geovax Inc
Publication of CA3011014A1 publication Critical patent/CA3011014A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001181—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3011014A 2016-01-08 2017-01-09 Compositions and methods for generating an immune response to a tumor associated antigen Pending CA3011014A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276479P 2016-01-08 2016-01-08
US62/276,479 2016-01-08
US201662301885P 2016-03-01 2016-03-01
US62/301,885 2016-03-01
PCT/US2017/012704 WO2017120577A1 (en) 2016-01-08 2017-01-09 Compositions and methods for generating an immune response to a tumor associated antigen

Publications (1)

Publication Number Publication Date
CA3011014A1 true CA3011014A1 (en) 2017-07-13

Family

ID=59274065

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3011014A Pending CA3011014A1 (en) 2016-01-08 2017-01-09 Compositions and methods for generating an immune response to a tumor associated antigen

Country Status (9)

Country Link
US (3) US11278607B2 (enExample)
EP (1) EP3402802B1 (enExample)
JP (3) JP7150611B2 (enExample)
CN (2) CN109071592B (enExample)
AU (2) AU2017206102C1 (enExample)
CA (1) CA3011014A1 (enExample)
ES (1) ES2944314T3 (enExample)
PL (1) PL3402802T3 (enExample)
WO (1) WO2017120577A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
BR112018015696A2 (pt) 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
WO2019040846A1 (en) * 2017-08-25 2019-02-28 Geovax Inc. IMMUNO-ONCOLOGY COMPOSITIONS AND METHODS OF USE THEREOF
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
US20210369825A1 (en) * 2018-10-05 2021-12-02 Nantcell, Inc. Cd40 and cd40l combo in an adv vaccine vehicle
CN114929268A (zh) * 2019-11-20 2022-08-19 巴法里安诺迪克有限公司 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途
JP2023513611A (ja) * 2020-02-14 2023-03-31 ゲオバックス インコーポレイテッド Ｓａｒｓ－ｃｏｖ２に対する免疫応答を誘導するためのワクチン及びその利用
JP7584763B2 (ja) * 2020-06-04 2024-11-18 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
JPH0795954B2 (ja) 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
ES2212795T3 (es) 1991-08-26 2004-08-01 Baxter Healthcare S.A. Virus de la viruela de las aves de corral recombinante.
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
EP0561034B1 (en) 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
WO1994012617A1 (en) 1992-11-25 1994-06-09 International Biotechnology Laboratories, Inc. Hepatitis b virus vaccines
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0942747A1 (en) 1996-08-26 1999-09-22 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
AUPP380598A0 (en) 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
AU2002211948B2 (en) 2000-03-02 2007-09-13 Emory University DNA expression vectors and methods of use
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
DE60234018D1 (de) 2001-03-08 2009-11-26 Univ Emory Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7211378B2 (en) * 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
US7025970B2 (en) 2002-03-15 2006-04-11 Baxter International Inc. Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods
NZ536501A (en) 2002-05-16 2006-08-31 Bavarian Nordic As Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
WO2004042001A2 (en) 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
AU2003251531A1 (en) * 2002-06-14 2003-12-31 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
DE10249390A1 (de) 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
US20040109876A1 (en) 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
DE60314541T2 (de) 2002-11-25 2008-02-28 Bavarian Nordic A/S Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
EP1601333B1 (en) 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US20060099225A1 (en) 2004-04-13 2006-05-11 Sina Bavari Generation of virus-like particles and use as panfilovirus vaccine
EP1766096B1 (en) 2004-05-25 2013-01-02 Oregon Health and Science University Hiv vaccination usingand hcmv-based vaccine vectors
WO2006026667A2 (en) 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
EP1683870A1 (en) 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
EP2527365A3 (en) * 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
WO2006130525A2 (en) * 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
ES2281252B1 (es) 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
ES2671230T3 (es) 2006-06-20 2018-06-05 Transgene Sa Procedimiento para producir poxvirus y composiciones de poxvirus
US20100047277A1 (en) 2006-07-13 2010-02-25 Compans Richard W Virosomes, methods of preparation, and immunogenic compositions
CN101563463B (zh) 2006-08-25 2013-03-27 美国国有健康与人类服务部(马里兰州) 修饰的安卡拉（mva）痘苗病毒基因的基因组中保守基因之间的基因间位点
US20090092628A1 (en) 2007-03-02 2009-04-09 James Mullins Conserved-element vaccines and methods for designing conserved-element vaccines
AU2008275513A1 (en) 2007-05-02 2009-01-15 Emory University Enhancement of glycoprotein incorporation into virus-like particles
AU2008257792B2 (en) 2007-05-31 2013-08-29 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
US11202775B2 (en) * 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
US20100330190A1 (en) 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
AU2009319979B2 (en) 2008-11-03 2016-10-20 Takeda Vaccines, Inc. Improved methods for isolating enveloped virus-based VLPs free of infectious agents
EP2478103A4 (en) 2009-09-16 2014-02-19 Univ Tulane LASSAVIRUS-like PARTICLES AND METHOD FOR THE PRODUCTION THEREOF
AP2012006258A0 (en) 2009-10-13 2012-06-30 Geovax Inc Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
AU2010306559B2 (en) * 2009-10-16 2015-07-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites
CN102844663B (zh) * 2010-01-27 2016-01-06 俄勒冈健康科学大学 基于巨细胞病毒的免疫原性制剂
AU2011217955A1 (en) 2010-02-18 2012-08-16 Emory University Vectors expressing HIV antigens and GM-CSF and related methods for generating an immune response
US20120052082A1 (en) 2010-04-09 2012-03-01 Zetra Biologicals, LLC Cross-protective influenza vaccine
US9526777B2 (en) 2010-04-16 2016-12-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
US20130236486A1 (en) 2010-06-11 2013-09-12 Mayo Foundation For Medical Education And Research Immunogenic vaccine
WO2012106231A2 (en) * 2011-01-31 2012-08-09 Baxter International Inc. Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
CN103945863A (zh) 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
US20130280215A1 (en) 2011-10-18 2013-10-24 Geovax, Inc. Mva vectors expressing polypeptides and having high level production in certain cell lines
US9463238B2 (en) 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
JP2015522580A (ja) 2012-07-06 2015-08-06 ノバルティス アーゲー 免疫学的組成物およびその使用
US9821046B2 (en) 2013-01-21 2017-11-21 Oxford University Innovation Limited Composition and uses thereof
WO2015009946A1 (en) 2013-07-17 2015-01-22 Emory University Method of increasing immune response to hiv antigens
CA3205348A1 (en) 2013-10-23 2015-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
WO2015066715A1 (en) 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
EP3142689B1 (en) * 2014-05-13 2020-11-11 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
SG10201901735XA (en) 2014-09-03 2019-03-28 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
WO2016068919A1 (en) 2014-10-29 2016-05-06 Geovax, Inc. Combination therapy for treating viral reservoirs
WO2016115116A1 (en) 2015-01-12 2016-07-21 Geovax, Inc. Compositions and methods for generating an immune response to a hemorrhagic fever virus
US10072058B2 (en) 2015-04-29 2018-09-11 Emory University Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
BR112018015696A2 (pt) 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
EP3416978A4 (en) 2016-02-16 2019-11-06 Geovax, Inc. MULTIVALENT HIV VACCINE BOOST COMPOSITION AND METHOD OF USE
CA3026054A1 (en) 2016-05-30 2017-12-07 Geovax Inc. Compositions and methods for generating an immune response to hepatitis b virus
WO2018195447A1 (en) 2017-04-20 2018-10-25 Geovax Labs, Inc. Recombinant mva-based hiv immunogens and uses thereof
WO2019018501A1 (en) 2017-07-18 2019-01-24 Geovax Inc. COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE
WO2019040846A1 (en) 2017-08-25 2019-02-28 Geovax Inc. IMMUNO-ONCOLOGY COMPOSITIONS AND METHODS OF USE THEREOF
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
WO2020247547A1 (en) 2019-06-03 2020-12-10 Geovax, Inc. Cancer vaccine compositions and methods for use thereof

Also Published As

Publication number Publication date
JP2019500907A (ja) 2019-01-17
ES2944314T3 (es) 2023-06-20
JP2022185011A (ja) 2022-12-13
US20230040403A1 (en) 2023-02-09
CN116064669A (zh) 2023-05-05
PL3402802T3 (pl) 2023-06-05
AU2021261945B2 (en) 2024-12-12
AU2017206102B2 (en) 2021-08-26
EP3402802A4 (en) 2019-08-21
EP3402802B1 (en) 2023-04-12
US12247214B2 (en) 2025-03-11
US20190290745A1 (en) 2019-09-26
WO2017120577A1 (en) 2017-07-13
EP3402802A1 (en) 2018-11-21
JP7150611B2 (ja) 2022-10-11
AU2021261945A1 (en) 2021-12-02
US11413341B2 (en) 2022-08-16
CN109071592A (zh) 2018-12-21
AU2017206102A1 (en) 2018-07-19
US20200289633A1 (en) 2020-09-17
CN109071592B (zh) 2022-07-19
JP2024056839A (ja) 2024-04-23
AU2017206102C1 (en) 2022-02-10
US11278607B2 (en) 2022-03-22

Similar Documents

Publication Publication Date Title
US12247214B2 (en) Vaccinia viral vectors encoding chimeric virus like particles
US20250025544A1 (en) Immune checkpoint inhibitor co-expression vectors
US20220160853A1 (en) Cancer vaccine compositions and methods for use thereof
WO2019226941A1 (en) Shared antigens
WO2020097393A1 (en) Alphavirus neoantigen vectors and interferon inhibitors
ES2626261T3 (es) Método de quimioinmunoterapia
US20230256088A1 (en) Immuno-oncology compositions and methods for use thereof
JP2019205482A (ja) 核酸分子ワクチン組成物およびその使用
KR20200076696A (ko) 백신 t 세포 인핸서
HK40093155A (zh) 用於产生对肿瘤相关抗原的免疫应答的组合物和方法
RU2812046C2 (ru) Способ продуцирования аренавируса, а также мутантов аренавируса с противоопухолевыми свойствами

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220107

EEER Examination request

Effective date: 20220107

EEER Examination request

Effective date: 20220107

EEER Examination request

Effective date: 20220107

EEER Examination request

Effective date: 20220107